Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ESC 2025

European Society of Cardiology (ESC) Congress - 2025

August 29 - September 1, 2025

  1. All
  2. Farxiga (dapagliflozin)
  3. Chronic Kindey Disease
  4. Dyslipidemia
  5. Hypertension
  6. Heart Failure/Chronic Kidney Disease
  7. Heart Failure
  8. Wainua (eplontersen)
  9. ATTR Amyloidosis
  10. Type 2 Diabetes
  11. Major bleeding
  12. Lokelma (Sodium zirconium cyclosilicate)

HTML

Sequencing in over 120,000 cases unveils the rare coding variant architecture of atrial fibrillation

HTML

A value-based analysis of the systematic use of dapagliflozin in patients with heart failure

HTML

EVOLUTION-HF DEallEF: a non-interventional study program of patients with heart failure and initiated on dapagliflozin: results of 1st interim analysis

HTML

Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure

HTML

Leveraging AI and clinical guidelines to identify undiagnosed and under-treated CKD patients for treatment optimisation

PDF

Cardiorenal outcomes and all-cause mortality in patients with comorbid heart failure and chronic kidney disease across three countries (The CaRe Study)

HTML

Chronic kidney disease in patients with heart failure in German primary care practices: the InspeCKD study

PDF

Laroprovstat (AZD0780), a novel, oral PCSK9 inhibitor with properties allowing for broad use,food-intake independency and co-administration with other lipid-lowering therapies

HTML

BaxHTN - Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension

HTML

High prevalence of aldosterone dysregulation in hypertensive adults tested for aldosterone and renin levels

PDF

Risk of cardiorenal and metabolic outcomes in inadequately controlled hypertension: insights from the ENLIGHTN study

PDF

Outcomes of aldosterone dysregulation in routine clinical care ADEL (Aldosterone Dysregulation Epidemiology Landscape) – a population-based study

PDF

Guideline-directed medical therapy use in patients with incident comorbid heart failure and chronic kidney disease (The CaRe Study)

PDF

Cardiorenal outcomes and all-cause mortality in patients with comorbid heart failure and chronic kidney disease across three countries (The CaRe Study)

HTML

Development and implementation of a heart failure dashboard for England: nationwide analysis of 1.4 million primary and secondary health care records

HTML

WATCH HF Awareness of prevalence, diagnosis and treatment of chronic heart failure in at risk patients in german primary care analysing real world data of chronic HF management in Germany

HTML

Unveiling gaps in heart failure management in Germany: a retrospective analysis of national data and healthcare utilisation patterns

HTML

Heart failure prevalence, medication prescription rates, and adverse outcomes in patients undergoing TAVI: the real-world data analysis

PDF

Guideline-directed medical therapy use in patients with incident comorbid heart failure and chronic kidney disease (The CaRe Study)

PDF

Cardiorenal outcomes and all-cause mortality in patients with comorbid heart failure and chronic kidney disease across three countries (The CaRe Study)

HTML

Development and implementation of a heart failure dashboard for England: nationwide analysis of 1.4 million primary and secondary health care records

HTML

WATCH HF Awareness of prevalence, diagnosis and treatment of chronic heart failure in at risk patients in german primary care analysing real world data of chronic HF management in Germany

HTML

Unveiling gaps in heart failure management in Germany: a retrospective analysis of national data and healthcare utilisation patterns

HTML

Heart failure prevalence, medication prescription rates, and adverse outcomes in patients undergoing TAVI: the real-world data analysis

PDF

Atrial structure and function in patients with amyloidosis: findings from the NEURO-TTRansform study

PDF

Early Symptoms and Medical History of Patients with Transthyretin Amyloidosis Cardiomyopathy: Results from the Multi-Country OverTTuRe Study

HTML

The incidence of death and risk factors for mortality in cardiac amyloidosis: an observational study in the UK clinical setting using electronic health records

HTML

OverTTuRe study: disease burden at diagnosis in ATTR amyloidosis patients with cardiac impairment in Spain

PDF

MaesTTRo: Initial findings from a pioneering prospective multi-country real-world study of patients with transthyretin amyloidosis

HTML

OverTTuRe study: disease burden at diagnosis in ATTR amyloidosis patients with cardiac impairment in Spain

HTML

Factor Xa inhibitor associated major bleeding characteristics, burden, and health resource utilization in Alberta, Canada - an observational population based study

HTML

Hyperkalaemia in patients with heart failure in German general practices: prevalence, diagnosis and treatment: The WATCH-K study

HTML

Sequencing in over 120,000 cases unveils the rare coding variant architecture of atrial fibrillation

HTML

A value-based analysis of the systematic use of dapagliflozin in patients with heart failure

HTML

EVOLUTION-HF DEallEF: a non-interventional study program of patients with heart failure and initiated on dapagliflozin: results of 1st interim analysis

HTML

Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure

HTML

Leveraging AI and clinical guidelines to identify undiagnosed and under-treated CKD patients for treatment optimisation

PDF

Cardiorenal outcomes and all-cause mortality in patients with comorbid heart failure and chronic kidney disease across three countries (The CaRe Study)

HTML

Chronic kidney disease in patients with heart failure in German primary care practices: the InspeCKD study

PDF

Laroprovstat (AZD0780), a novel, oral PCSK9 inhibitor with properties allowing for broad use,food-intake independency and co-administration with other lipid-lowering therapies

HTML

BaxHTN - Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension

HTML

High prevalence of aldosterone dysregulation in hypertensive adults tested for aldosterone and renin levels

PDF

Risk of cardiorenal and metabolic outcomes in inadequately controlled hypertension: insights from the ENLIGHTN study

PDF

Outcomes of aldosterone dysregulation in routine clinical care ADEL (Aldosterone Dysregulation Epidemiology Landscape) – a population-based study

PDF

Guideline-directed medical therapy use in patients with incident comorbid heart failure and chronic kidney disease (The CaRe Study)

PDF

Cardiorenal outcomes and all-cause mortality in patients with comorbid heart failure and chronic kidney disease across three countries (The CaRe Study)

HTML

Development and implementation of a heart failure dashboard for England: nationwide analysis of 1.4 million primary and secondary health care records

HTML

WATCH HF Awareness of prevalence, diagnosis and treatment of chronic heart failure in at risk patients in german primary care analysing real world data of chronic HF management in Germany

HTML

Unveiling gaps in heart failure management in Germany: a retrospective analysis of national data and healthcare utilisation patterns

HTML

Heart failure prevalence, medication prescription rates, and adverse outcomes in patients undergoing TAVI: the real-world data analysis

PDF

Atrial structure and function in patients with amyloidosis: findings from the NEURO-TTRansform study

PDF

Early Symptoms and Medical History of Patients with Transthyretin Amyloidosis Cardiomyopathy: Results from the Multi-Country OverTTuRe Study

HTML

The incidence of death and risk factors for mortality in cardiac amyloidosis: an observational study in the UK clinical setting using electronic health records

HTML

OverTTuRe study: disease burden at diagnosis in ATTR amyloidosis patients with cardiac impairment in Spain

PDF

MaesTTRo: Initial findings from a pioneering prospective multi-country real-world study of patients with transthyretin amyloidosis

HTML

OverTTuRe study: disease burden at diagnosis in ATTR amyloidosis patients with cardiac impairment in Spain

HTML

Factor Xa inhibitor associated major bleeding characteristics, burden, and health resource utilization in Alberta, Canada - an observational population based study

HTML

Hyperkalaemia in patients with heart failure in German general practices: prevalence, diagnosis and treatment: The WATCH-K study

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States